# BioLineRx Ltd.: Form 20-F for the period ended Dec 31, 2019

- Company: [BioLineRx Ltd.](/companies/blrx.md) (CIK 1498403)
- Form: 20-F
- Filed: 2020-03-12
- Accepted by EDGAR: Mar 12, 2020, 11:07 ET
- Period: 2019-12-31
- Accession: 0001178913-20-000790
- Inline XBRL: yes
- Main document: https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/zk2024121.htm
- All documents and exhibits: https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/

## Figures reported in this filing

Standardized XBRL line items for the period ended 2019-12-31.

| Line item | Period | Value | XBRL concept |
| --- | --- | ---: | --- |
| Operating income | 12 months, 2019-01-01 to 2019-12-31 | −$28.1m | ifrs-full:ProfitLossFromOperatingActivities |
| Net income | 12 months, 2019-01-01 to 2019-12-31 | −$25.4m | ifrs-full:ProfitLoss |
| Operating cash flow | 12 months, 2019-01-01 to 2019-12-31 | −$22.7m | ifrs-full:CashFlowsFromUsedInOperatingActivities |
| Capital expenditure | 12 months, 2019-01-01 to 2019-12-31 | $67.0k | ifrs-full:PurchaseOfPropertyPlantAndEquipmentClassifiedAsInvestingActivities |
| Cash and equivalents | at 2019-12-31 | $5.3m | ifrs-full:CashAndCashEquivalents |
| Current assets | at 2019-12-31 | $28.2m | ifrs-full:CurrentAssets |
| Total assets | at 2019-12-31 | $53.6m | ifrs-full:Assets |
| Current liabilities | at 2019-12-31 | $12.0m | ifrs-full:CurrentLiabilities |
| Total liabilities | at 2019-12-31 | $20.2m | ifrs-full:Liabilities |
| Shareholders' equity | at 2019-12-31 | $33.4m | ifrs-full:Equity |
| Shares outstanding | at 2019-12-31 | 171,269,528 shares | dei:EntityCommonStockSharesOutstanding |

## Sections

Sections are extracted only from 10-K and 10-Q reports. Read this filing’s documents on sec.gov. https://www.sec.gov/Archives/edgar/data/1498403/000117891320000790/zk2024121.htm

Filed Mar 12, 2020.
Source: SEC EDGAR, the filing index for accession 0001178913-20-000790. Last ingested by Listed: Oct 24, 2026, 15:07 ET. No prices; not investment advice.
